PROS1 and COVID-19: To design a VLP, the company selected the spike protein (S protein) of SARS-CoV-2, the most widely used target antigen for COVID-19 vaccines among the structural envelope protein (E), membrane protein (M), and nucleocapsid protein (N) because of its high immunogenicity and crucial role in viral cell entry [90,91,92].